Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
摘要
<p>The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.</p>
